Abstract: Gastric cancer is one of the most common malignant tumors, characterized by strong heterogeneity, high aggressiveness and complicated molecular type. Although comprehensive treatments such as surgery, chemo‑radiotherapy, targeted therapy, and immunotherapy have improved the survival of patients with gastric cancer, occult metastasis or recurrence often cannot be detected in a timely manner, seriously affecting the prognosis of patients. The evaluation of molecular residual disease (MRD) based on circulating tumor DNA detection has been preliminarily applied to various solid tumors, and has been confirmed in clinical studies to have good predictive ability for recurrence and prognosis. Currently, a unified consensus on MRD detection and clinical application for gastric cancer has not yet been established in China. Therefore, this consensus aims to promote the standardization of gastric cancer MRD detection in clinical application, and bring more accurate clinical treatment strategies to patients with gastric cancer.